18
Participants
Start Date
December 31, 2026
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
hEGFRvIII-CD3 (BRiTE)
Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells
Duke University Medical Center, Durham
Lead Sponsor
Duke University
OTHER